Latest Hitiq (ASX:HIQ) News

HITIQ has secured a $1.5 million R&D tax incentive loan facility and drawn half the available funding, providing immediate liquidity while adding interest-bearing debt. The arrangement with a related party also puts shareholder approval of proposed security in focus.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

Small-cap tech delivered a split screen this week. Contract wins, capital raisings and takeover steps pushed several stocks higher, while weaker sales and heavy dilution fears hit others hard. The biggest swing came from 8common, while Atomos and FirstWave led the falls for very different reasons.

HitIQ Limited attributes recent share price and volume spikes to a recent $1.4 million private placement and investor buying, denying any undisclosed material information.

Big swings hit ASX tech as tiny GCM surged, Objective slumped on a Defence contract loss, and DXN fell despite landing new work. Away from the biggest price moves, the week was packed with raisings, acquisitions and fresh AI, quantum and enterprise contract news.

HITIQ Limited has secured $1.4 million through a private placement of 200 million shares at 0.7 cents each, accompanied by options exercisable until 2029. The capital will bolster its balance sheet and back expansion and commercialisation efforts.

Space batteries, telecom AI and a healthcare software leadership change drove the week’s biggest moves in small-cap tech. Capital raisings and debt deals also shaped trading, with several early jumps fading as investors weighed dilution and execution risk.

HITIQ Limited secured a Federal Court order extending the quotation period for its HIQOA listed options on the ASX, resolving a regulatory timing issue and validating the delayed admission.

Capital moves, contract wins and AI product pushes drove a busy week across small and mid-cap technology stocks. Hydrix, Complii and ClearVue led the board, while investors sold names where early excitement gave way to dilution concerns or softer earnings detail.

HIQ Limited has locked in non-dilutive funding from the Victorian Government to underpin a $4.9 million project expanding its manufacturing and research footprint in Victoria, supporting its global growth ambitions.